<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - 獲取免費報告) 的股價在週一的交易中突破了其 50 日移動平均線。該股票的 50 日移動平均價為 3.26 美元，最高交易價為 3.35 美元。Oramed Pharmaceuticals 的股票最後交易價為 3.31 美元，成交量為 368,355 股。</p>
<p>獲取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>一些股票分析師最近對 ORMP 股票進行了評估。Weiss Ratings 在 12 月 29 日的報告中重申了對 Oramed Pharmaceuticals 股票的 “持有（c）” 評級。Wall Street Zen 在 11 月 1 日的研究報告中將 Oramed Pharmaceuticals 的股票評級提升至 “持有”。根據 MarketBeat.com 的數據，一位股票研究分析師對該股票給予了持有評級，目前該公司的共識評級為 “持有”。</p>
<p><strong>閲讀我們對 ORMP 的最新股票分析</strong></p>
<h2>Oramed Pharmaceuticals 價格表現</h2>
<p>該公司的 50 日移動平均價格為 3.26 美元，200 日移動平均價格為 2.71 美元。該公司的市值為 1.3174 億美元，市盈率為 2.63，貝塔值為 1.34。</p>
<h2>Oramed Pharmaceuticals 宣佈分紅</h2>
<p>該公司最近還披露了一項分紅，該分紅於 1 月 26 日（週一）支付。1 月 16 日（週五）的股東獲得每股 0.25 美元的分紅。該分紅的除息日期為 1 月 16 日（週五）。Oramed Pharmaceuticals 的分紅支付比率目前為 19.84%。</p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者和對沖基金最近買賣了該股票的股份。美國銀行在第三季度將其在 Oramed Pharmaceuticals 的持股增加了 4.4%。美國銀行目前擁有 149,667 股該生物技術公司的股票，價值 395,000 美元，此前在上個季度購買了 6,261 股。XTX Topco Ltd 在第四季度將其在 Oramed Pharmaceuticals 的股份增加了 59.9%。XTX Topco Ltd 目前擁有 38,182 股該生物技術公司的股票，價值 109,000 美元，此前在此期間購買了 14,297 股。Jane Street Group LLC 在第一季度將其在 Oramed Pharmaceuticals 的持股增加了 35.3%。Jane Street Group LLC 目前擁有 67,173 股該生物技術公司的股票，價值 144,000 美元，此前在上個季度增加了 17,510 股。Squarepoint Ops LLC 在第四季度將其在 Oramed Pharmaceuticals 的股份增加了 95.1%。Squarepoint Ops LLC 目前擁有 58,272 股該生物技術公司的股票，價值 166,000 美元，此前在上個季度增加了 28,406 股。最後，Quadrature Capital Ltd 在第四季度獲得了 Oramed Pharmaceuticals 的新頭寸，價值約 119,000 美元。12.73% 的股票由機構投資者和對沖基金持有。</p>
<h2>Oramed Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Oramed Pharmaceuticals Inc 是一家臨牀階段的生物技術公司，專注於開發專有的口服藥物遞送系統，初步重點是糖尿病管理。公司總部位於以色列耶路撒冷，利用其專利的蛋白質包封技術 “口服遞送平台”，將注射療法轉變為患者友好的口服制劑。Oramed 的平台旨在保護敏感的蛋白質和肽免受胃腸道降解，從而實現成功的吸收和系統遞送。</p>
<p>該公司的主要候選藥物 ORMD-0801 是一種用於 2 型糖尿病患者的口服胰島素膠囊，目前正在進行第三階段臨牀試驗。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Oramed Pharmaceuticals 更好</li>
<li>埃隆·馬斯克已經讓我成為 “富有的人”</li>
<li>埃隆的秘密人工智能合作伙伴？</li>
<li>銀價 500 美元？“赤字數學” 認為這是可能的。</li>
<li>埃隆·馬斯克：這可能將 100 美元變成 100,000 美元</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Oramed Pharmaceuticals 嗎？</h2>
<p>在你考慮 Oramed Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前……而 Oramed Pharmaceuticals 並不在名單上。</p>
<p>雖然 Oramed Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Oramed制藥

<p>Oramed 製藥（NASDAQ:ORMP）股票價格超過其 50 日移動平均線 3.26 美元，最高達到 3.35 美元，最終收於 3.31 美元。該公司的市值為 1.3174 億美元，市盈率為 2.63。分析師對該股票維持 “持有” 的共識評級。最近，Oramed 宣佈每股派息 0.25 美元，派息率為 19.84%。機構投資者持有該股票的 12.73%，多個公司在其持倉上有顯著增加</p>

<p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s stock price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.26 and traded as high as $3.35. Oramed Pharmaceuticals shares last traded at $3.31, with a volume of 368,355 shares trading hands.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - 獲取免費報告) 的股價在週一的交易中突破了其 50 日移動平均線。該股票的 50 日移動平均價為 3.26 美元，最高交易價為 3.35 美元。Oramed Pharmaceuticals 的股票最後交易價為 3.31 美元，成交量為 368,355 股。</p>
</div><p>Get <strong>Oramed Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Oramed Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of equities analysts have recently weighed in on ORMP shares. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen raised shares of Oramed Pharmaceuticals to a &#34;hold&#34; rating in a research note on Saturday, November 1st. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34;.</p>
<div class="lb-trans"><p>一些股票分析師最近對 ORMP 股票進行了評估。Weiss Ratings 在 12 月 29 日的報告中重申了對 Oramed Pharmaceuticals 股票的 “持有（c）” 評級。Wall Street Zen 在 11 月 1 日的研究報告中將 Oramed Pharmaceuticals 的股票評級提升至 “持有”。根據 MarketBeat.com 的數據，一位股票研究分析師對該股票給予了持有評級，目前該公司的共識評級為 “持有”。</p>
</div><p><strong>Read Our Latest Stock Analysis on ORMP</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 ORMP 的最新股票分析</strong></p>
</div><h2>Oramed Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 價格表現</h2>
</div><p>The company's 50 day moving average price is $3.26 and its 200 day moving average price is $2.71. The firm has a market cap of $131.74 million, a PE ratio of 2.63 and a beta of 1.34.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 3.26 美元，200 日移動平均價格為 2.71 美元。該公司的市值為 1.3174 億美元，市盈率為 2.63，貝塔值為 1.34。</p>
</div><h2>Oramed Pharmaceuticals Announces Dividend</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 宣佈分紅</h2>
</div><p>The business also recently disclosed a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals's dividend payout ratio is currently 19.84%.</p>
<div class="lb-trans"><p>該公司最近還披露了一項分紅，該分紅於 1 月 26 日（週一）支付。1 月 16 日（週五）的股東獲得每股 0.25 美元的分紅。該分紅的除息日期為 1 月 16 日（週五）。Oramed Pharmaceuticals 的分紅支付比率目前為 19.84%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE raised its position in Oramed Pharmaceuticals by 4.4% in the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company's stock valued at $395,000 after purchasing an additional 6,261 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company's stock worth $109,000 after buying an additional 14,297 shares during the period. Jane Street Group LLC raised its holdings in Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 17,510 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company's stock worth $166,000 after acquiring an additional 28,406 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in Oramed Pharmaceuticals during the 4th quarter worth approximately $119,000. 12.73% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近買賣了該股票的股份。美國銀行在第三季度將其在 Oramed Pharmaceuticals 的持股增加了 4.4%。美國銀行目前擁有 149,667 股該生物技術公司的股票，價值 395,000 美元，此前在上個季度購買了 6,261 股。XTX Topco Ltd 在第四季度將其在 Oramed Pharmaceuticals 的股份增加了 59.9%。XTX Topco Ltd 目前擁有 38,182 股該生物技術公司的股票，價值 109,000 美元，此前在此期間購買了 14,297 股。Jane Street Group LLC 在第一季度將其在 Oramed Pharmaceuticals 的持股增加了 35.3%。Jane Street Group LLC 目前擁有 67,173 股該生物技術公司的股票，價值 144,000 美元，此前在上個季度增加了 17,510 股。Squarepoint Ops LLC 在第四季度將其在 Oramed Pharmaceuticals 的股份增加了 95.1%。Squarepoint Ops LLC 目前擁有 58,272 股該生物技術公司的股票，價值 166,000 美元，此前在上個季度增加了 28,406 股。最後，Quadrature Capital Ltd 在第四季度獲得了 Oramed Pharmaceuticals 的新頭寸，價值約 119,000 美元。12.73% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Oramed Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Oramed Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed's platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.</p>
<div class="lb-trans"><p>Oramed Pharmaceuticals Inc 是一家臨牀階段的生物技術公司，專注於開發專有的口服藥物遞送系統，初步重點是糖尿病管理。公司總部位於以色列耶路撒冷，利用其專利的蛋白質包封技術 “口服遞送平台”，將注射療法轉變為患者友好的口服制劑。Oramed 的平台旨在保護敏感的蛋白質和肽免受胃腸道降解，從而實現成功的吸收和系統遞送。</p>
</div><p>The company's lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.</p>
<div class="lb-trans"><p>該公司的主要候選藥物 ORMD-0801 是一種用於 2 型糖尿病患者的口服胰島素膠囊，目前正在進行第三階段臨牀試驗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Oramed Pharmaceuticals</li>
<li>Elon Musk already made me a “wealthy man”</li>
<li>Elon’s Secret AI Partner?</li>
<li>Silver $500? The &#34;Deficit Math&#34; says it's possible.</li>
<li>Elon Musk: This Could Turn $100 into $100,000</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Oramed Pharmaceuticals 更好</li>
<li>埃隆·馬斯克已經讓我成為 “富有的人”</li>
<li>埃隆的秘密人工智能合作伙伴？</li>
<li>銀價 500 美元？“赤字數學” 認為這是可能的。</li>
<li>埃隆·馬斯克：這可能將 100 美元變成 100,000 美元</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oramed Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Oramed Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Oramed Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Oramed Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在購買，以便在更廣泛的市場注意到之前……而 Oramed Pharmaceuticals 並不在名單上。</p>
</div><p>While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Oramed Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Oramed 製藥（NASDAQ:ORMP）的股價突破了 50 日移動平均線 - 以下是原因